Ocugen, Inc.
Bioscience Park Center
12635 E Montview Boulevard
Aurora
Colorado
80045
United States
Tel: 720-859-3549
Website: http://ocugen.com/
211 articles about Ocugen, Inc.
-
Ocugen gets the go-ahead from the FDA to trial its late-stage regenerative cell therapy.
-
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®Important next step for Ocugen’s regenerative cell therapy in orthopedics since announcing pipeline expansion in May 2022
12/16/2022
Ocugen, Inc. today announced that the U.S. Food & Drug Administration (FDA) agreed to Ocugen’s proposed control and overall design for the Phase 3 study of NeoCart ®, a regenerative cell therapy for the repair of full-thickness lesions of the knee cartilage in adults.
-
Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital AmaurosisU.S. Food & Drug Administration (FDA) acknowledges the potential of OCU400 to treat rare inherited retinal diseases
12/15/2022
Ocugen, Inc. announced that the FDA granted orphan drug designations to OCU400—human nuclear hormone receptor subfamily 2 group E member 3 —for the treatment of retinitis pigmentosa and Leber congenital amaurosis.
-
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
12/7/2022
Ocugen, Inc. today announced that the Data Safety and Monitoring Board (DSMB) for the OCU400 clinical trial recently convened and established high dose as the maximum tolerable dose (MTD) in the dose-escalation phase of the study.
-
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
11/28/2022
Ocugen, Inc. today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, Ph.D., will participate in the 3rd Annual Dry AMD Therapeutics Summit at the Revere Hotel in Boston, Mass. from November 30-December 2, 2022.
-
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
11/8/2022
Ocugen, Inc. today reported financial results for the quarter ended September 30, 2022, and provided a general business update.
-
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
10/27/2022
Ocugen, Inc. today announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2022 financial results and provide a business update at 8:30 a.m. ET on Tuesday, November 8, 2022.
-
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
10/19/2022
Ocugen, Inc. today announced that it will host an in-person Research & Development (R&D) Day on Tuesday, November 1, 2022.
-
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2
10/12/2022
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Independent Data and Safety Monitoring Board (DSMB) for the OCU400 Phase 1/2 clinical trial completed a review of safety data for subjects enrolled in Cohort 2 and recommends proceeding to enroll subjects in Cohort 3.
-
Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences
10/6/2022
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company will present at two important conferences this month.
-
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
9/29/2022
Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY.
-
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
9/28/2022
Ocugen, Inc. announced that the company has entered into an exclusive license agreement with Washington University in St. Louis, MO for the rights to develop, manufacture and commercialize its proprietary, intranasally delivered COVID-19 vaccine in the United States, Europe, and Japan.
-
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 16, 2022
9/16/2022
Ocugen, Inc. announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 148,800 shares of its common stock and restricted stock units covering an aggregate of 40,092 shares of common stock to five newly hired team members.
-
There's a new collaboration in the Parkinson's disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
-
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology
9/14/2022
Ocugen, Inc. announced the publication “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” appeared in Frontiers in Immunology.
-
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.
-
Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference
9/8/2022
Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Company’s Chief Scientific Officer, Arun Upadhyay, PhD, will be among the featured speakers at the 3rd Annual Gene Therapy for Ophthalmic Disorders conference.
-
Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 in New York, NY.
-
Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer
9/1/2022
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer.
-
Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
8/12/2022
Ocugen, Inc announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will deliver a virtual presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17.